Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Berenguer J, Díez C, Martín-Vicente M, Micán R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S, Jarrín I. Berenguer J, et al. Among authors: pulido f. Clin Microbiol Infect. 2021 Nov;27(11):1678-1684. doi: 10.1016/j.cmi.2021.06.023. Epub 2021 Jun 26. Clin Microbiol Infect. 2021. PMID: 34186209 Free PMC article. Review.
Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
Berenguer J, González J, Pulido F, Padilla B, Casado JL, Rubio R, Arribas JR; Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis. Berenguer J, et al. Among authors: pulido f. Clin Infect Dis. 2002 Feb 1;34(3):394-7. doi: 10.1086/338401. Epub 2001 Dec 19. Clin Infect Dis. 2002. PMID: 11753827 Clinical Trial.
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).
Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Del Palacio A, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Arribas JR, et al. Among authors: pulido f. AIDS. 2002 Jul 26;16(11):1554-6. doi: 10.1097/00002030-200207260-00014. AIDS. 2002. PMID: 12131195 Clinical Trial.
Underpowered clinical trials of antiretroviral treatment.
Arribas JR, Pulido F. Arribas JR, et al. Among authors: pulido f. JAMA. 2002 Nov 6;288(17):2120; author reply 2120-1. doi: 10.1001/jama.288.17.2120. JAMA. 2002. PMID: 12413367 No abstract available.
Treatment of advanced HIV infection.
Pulido F, Arribas JR. Pulido F, et al. J Antimicrob Chemother. 2003 Feb;51(2):225-7. doi: 10.1093/jac/dkg065. J Antimicrob Chemother. 2003. PMID: 12562685 Review. No abstract available.
Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].
Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Berenguer J, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2004 Mar;22(3):160-76. doi: 10.1016/s0213-005x(04)73057-8. Enferm Infecc Microbiol Clin. 2004. PMID: 14987537 Review. English, Spanish.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR. Montes ML, et al. Among authors: pulido f. J Antimicrob Chemother. 2005 May;55(5):800-4. doi: 10.1093/jac/dki063. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761071 Clinical Trial.
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, González-García JJ, Cepeda C, Hervás R, Paño JR, Gaya F, Carcas A, Montes ML, Costa JR, Peña JM. Arribas JR, et al. Among authors: pulido f. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4. J Acquir Immune Defic Syndr. 2005. PMID: 16249701 Clinical Trial.
335 results